News & Events

Get the latest news and updates from ImmunityBio

Recent Research

See All Research

Pipeline

Our therapies are tailored to each patient’s needs. We employ a “triangle” offense designed to deliver durable, complete responses in cancer and infectious diseases.

See Pipeline

Investigational Therapies

Cancer Therapy Clinical Trials

ImmunityBio’s platform addresses the entire immune system beyond the limitations of chimeric antigen receptor T-cell (CAR-T) therapies and checkpoint inhibitors by activating the natural killer cell, T cells, macrophages, and inducing memory through dendritic cells. Clinical trials orchestrating these unique therapies, which harness both the innate and adaptive immune system, are in progress across multiple tumor types.

Lynch Syndrome Non-Small Cell Lung Cancer Bladder Cancer Glioblastoma

Viral Therapy Clinical Trials

Infected cells, like cancer cells, can be exposed to enable recognition and killing by our natural killer cell and T cell platforms. Current clinical trials addressing HIV, COVID, and infectious diseases are in progress. A second-generation human adenovirus (hAd5) vector serves as a platform to deliver specific viral sequences and educate our immune system to clear the infected cells. The potential to administer these vaccines orally will enable greater global access.

HIV

How Can ImmunityBio Help You?

Solutions for Patients

Many therapies for treating cancer and infectious disease severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Learn More

Opportunities for Trial Investigators

Immunotherapies and cell therapies are key to future cancer treatments. Our investigational IL-15 superagonist, N-803, and NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.

Learn More

Solutions for Research Scientists

Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

Learn More

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

About Us
Press Release
September 21, 2020

NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit

EL SEGUNDO, Calif. –Sep. 21, 2020– NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET. The conference presentation will be available…
Read More
Press Release
August 24, 2020

NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics

Both companies agree to share equally in costs relating to COVID-19 therapeutics and vaccine candidates globally; global net profits to be shared 60%/40% in favor of the company contributing the product EL SEGUNDO and CULVER CITY, Calif., August 24, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and…
Read More
Press Release
August 10, 2020

Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment

CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy…
Read More
Press Release
August 3, 2020

ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins

Preclinical results show this next generation Adeno (hAd5) vaccine, which targets both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, generates CD4+ and CD8+ T-cell responses, both of which can form long-term immune memory.  Inclusion of nucleocapsid in this vaccine construct potentially overcomes the risk of emerging mutations in spike, which might limit…
Read More
Press Release
June 29, 2020

NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

EL SEGUNDO, Calif — Jun. 29, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock (4,811,500 shares at a price to the public of $9.50 per…
Read More
Press Release
June 25, 2020

NantKwest Announces Pricing of Public Offering of Common Stock

EL SEGUNDO, Calif.–Jun. 25, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares at a price to the public of $9.50 per share and 3,710,000 shares…
Read More
Press Release
June 24, 2020

NantKwest Announces Proposed Public Offering of Common Stock

EL SEGUNDO, Calif.—Jun. 24, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, NantKwest expects to grant the underwriters a…
Read More
Older Posts
Newer Posts
Sort by:
All categories
or
All years
View All